Correction to: Cell Death and Disease (2014) 5, e1247; doi:10.1038/cddis.2014.222; published online 22 May 2014
Since the publication of this paper the authors have noted an error in Figures 2b and c. The position of the western blot labels ‘siNC’and ‘siSPAG5’ was incorrect. This has now been rectified, the correct figure is shown below and the corrected article appears online together with this corrigendum.
SPAG5 knockdown efficiency in cervical cancer cell lines. (a) Western blot of siRNA specific to SPAG5 knockdown efficiency in SiHa cells (left), gradient analysis (middle); mRNA expression (right) was detected by qRT-PCR. (b) Transient knockdown reflected in levels of SPAG5 protein (left) and mRNA (right) in HeLa cells. (c) SPAG5 expression in shSPAG5 lines detected by western blotting (right) and qRT-PCR (left)
The authors would like to apologize for any inconvenience this may have caused.
Additional information
The online version of the original article can be found at 10.1038/cddis.2014.222
Rights and permissions
About this article
Cite this article
Yuan, LJ., Li, JD., Zhang, L. et al. Erratum: SPAG5 upregulation predicts poor prognosis in cervical cancer patients and alters sensitivity to taxol treatment via the mTOR signaling pathway. Cell Death Dis 6, e1784 (2015). https://doi.org/10.1038/cddis.2015.163
Published:
Issue date:
DOI: https://doi.org/10.1038/cddis.2015.163
This article is cited by
-
SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer
Journal of Hematology & Oncology (2019)
-
SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying β-catenin degradation
Journal of Experimental & Clinical Cancer Research (2018)
